19.71

1.89% -0.38

Pre-market: 20.05 0.34 +1.73%

Amphastar Pharmaceuticals Inc (AMPH)

Overview News Price History Option Chain Financials Why AMPH Down? Discussions Forecast

Amphastar Pharmaceuticals Inc stock is traded at $19.71, with a volume of 528.51K. It is down -1.89% in the last 24 hours and up +16.83% over the past month. Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

Previous Close:

$20.09

Open:

$20.11

24h Volume:

528.51K

Relative Volume:

0.89

Market Cap:

$869.07M

Revenue:

$720.53M

Net Income/Loss:

$79.23M

P/E Ratio:

11.84

EPS:

1.6648

Net Cash Flow:

$132.94M

1W Performance:

+1.65%

1M Performance:

+16.83%

6M Performance:

-25.09%

1Y Performance:

-23.66%

1-Day Range:

$19.59

$20.29

1-Week Range:

$19.53

$20.77

52-Week Range:

$16.64

$31.26

Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile

Name

Amphastar Pharmaceuticals Inc

Sector

Healthcare (1104)

Industry

Drug Manufacturers - Specialty & Generic (88)

Phone

909-980-9484

Address

11570 SIXTH STREET, RANCHO CUCAMONGA, CA

Employee

1,976

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

AMPH's Discussions on Twitter

Compare AMPH vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMPH Amphastar Pharmaceuticals Inc	19.71	869.07M	720.53M	79.23M	132.94M	1.6648
TAK Takeda Pharmaceutical Co Adr	15.77	49.83B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.07	40.04B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	33.69	39.23B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	79.95	33.52B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	549.57	23.33B	3.17B	1.29B	1.01B	27.09

Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Downgrade	Jefferies	Buy → Hold
Dec-09-25	Initiated	Barclays	Equal Weight
Aug-12-25	Upgrade	Needham	Hold → Buy
May-12-25	Downgrade	JP Morgan	Overweight → Neutral
Feb-04-25	Downgrade	Piper Sandler	Overweight → Neutral
Nov-22-24	Initiated	Wells Fargo	Equal Weight
Mar-05-24	Initiated	JP Morgan	Overweight
Nov-17-23	Initiated	BofA Securities	Neutral
Jul-25-23	Resumed	Jefferies	Buy
Oct-21-22	Resumed	Jefferies	Buy
Jul-29-22	Initiated	CapitalOne	Overweight
Jan-07-22	Upgrade	Piper Sandler	Neutral → Overweight
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-05-20	Upgrade	Northland Capital	Market Perform → Outperform
May-01-20	Initiated	Northland Capital	Outperform
Mar-13-19	Downgrade	Needham	Buy → Hold
Mar-13-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-10-18	Reiterated	Needham	Buy
Mar-13-18	Reiterated	Needham	Buy
Dec-01-17	Reiterated	Needham	Buy
Nov-09-17	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-27-17	Reiterated	Needham	Buy
Mar-14-17	Downgrade	Raymond James	Strong Buy → Outperform
Aug-09-16	Reiterated	Needham	Buy
May-10-16	Reiterated	Needham	Buy
Feb-19-16	Initiated	Wells Fargo	Outperform
Jun-19-15	Reiterated	Needham	Buy
Jun-03-15	Initiated	Raymond James	Strong Buy
Jul-21-14	Initiated	Needham	Buy

View All

Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News

Jun 14, 2026

Amphastar Pharmaceuticals (AMPH) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Challenging QuarterFull Year Guidance - newsline.com

Jun 14, 2026

Jun 13, 2026

(AMPH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Jun 13, 2026

Jun 12, 2026

Healthcare Stock Picks: RadNet and Amphastar to Sell, One Stock to Watch | June 2026News and Statistics - IndexBox

Jun 12, 2026

Jun 11, 2026

Amphastar Pharmaceuticals pivots to proprietary drugs, biosimilars for growth - MSN

Jun 11, 2026

Jun 10, 2026

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth - MarketBeat

Jun 10, 2026

Jun 09, 2026

How The Investment Story For Amphastar Pharmaceuticals (AMPH) Is Evolving Without New Valuation Shifts - Yahoo Finance

Jun 09, 2026

Jun 08, 2026

Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged - GlobeNewswire

Jun 08, 2026

Jun 04, 2026

Amphastar Pharmaceuticals sees generic Atrovent fueling 2026 growth despite BAQSIMI drag - MSN

Jun 04, 2026

Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20 - Moomoo

Jun 04, 2026

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag - MarketBeat

Jun 04, 2026

Jun 03, 2026

Amphastar (AMPH) director awarded RSUs and options with tax withholding update - Stock Titan

Jun 03, 2026

Amphastar Pharmaceuticals (AMPH) director receives RSUs and options grant - Stock Titan

Jun 03, 2026

Deflin Gayle awarded RSUs and stock options at Amphastar (NASDAQ: AMPH) - Stock Titan

Jun 03, 2026

Amphastar (AMPH) director Diane Gerst receives RSUs and stock option grant - Stock Titan

Jun 03, 2026